Showing results (401-410 of 599) with videos related to
Sort By:
Pageof 60
Annals of the Rheumatic Diseases|September 29, 2020
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR databaseAnna-Maria Hoffmann-Vold, Yannick Allanore, Margarida Alves, et al.The Lancet. Rheumatology|October 17, 2025
Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosisJohn D Pauling, Yannick Allanore, Maya H Buch, et al.Rheumatology (Oxford, England)|February 5, 2025
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosisChristopher P Denton, Otylia Kowal-Bielecka, Susanna M Proudman, et al.Arthritis Research & Therapy|April 17, 2015
Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosisMaria Arismendi, Matthieu Giraud, Nadira Ruzehaji, et al.Journal of Autoimmunity|June 26, 2026
High-intensity immunosuppression versus modern standard care in poor-prognosis diffuse cutaneous systemic sclerosis: A propensity-matched studyLucas Khellaf, Rémi Khellaf, Pierre Pinson, et al.Rheumatology (Oxford, England)|May 16, 2020
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre studyCorrado Campochiaro, Giacomo De Luca, Maria Grazia Lazzaroni, et al.Arthritis Care & Research|September 5, 2023
Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?Elisabeth Deibel, Patricia E Carreira, Madelon Vonk, et al.Arthritis Research & Therapy|February 1, 2018
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR groupSabine Adler, Dörte Huscher, Elise Siegert, et al.Arthritis Research & Therapy|May 20, 2015
A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) gene and systemic sclerosisRoberta Goncalves Marangoni, Benjamin D Korman, Yannick Allanore, et al.Rheumatology (Oxford, England)|February 5, 2017
The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) studyOtylia Kowal-Bielecka, Sylwia Chwiesko-Minarowska, Pawel L Bernatowicz, et al.Pageof 60